Author
Listed:
- Henry W. Bell
(University of New South Wales)
- Ruopeng Feng
(St. Jude Children’s Research Hospital)
- Manan Shah
(University of New South Wales)
- Yu Yao
(St. Jude Children’s Research Hospital)
- James Douglas
(St. Jude Children’s Research Hospital)
- Phillip A. Doerfler
(St. Jude Children’s Research Hospital
Versiti Blood Research Institute)
- Thiyagaraj Mayuranathan
(St. Jude Children’s Research Hospital
Christian Medical College Vellore Bagayam Campus)
- Michael F. O’Dea
(University of New South Wales)
- Yichao Li
(St. Jude Children’s Research Hospital)
- Yong-Dong Wang
(St. Jude Children’s Research Hospital)
- Jingjing Zhang
(St. Jude Children’s Research Hospital)
- Joel P. Mackay
(University of Sydney)
- Yong Cheng
(St. Jude Children’s Research Hospital)
- Kate G. R. Quinlan
(University of New South Wales)
- Mitchell J. Weiss
(St. Jude Children’s Research Hospital)
- Merlin Crossley
(University of New South Wales)
Abstract
β-hemoglobinopathies caused by mutations in adult-expressed HBB can be treated by re-activating the adjacent paralogous genes HBG1 and HBG2 (HBG), which are normally silenced perinatally. Although HBG expression is induced by global demethylating drugs, their mechanism is poorly understood, and toxicity limits their use. We identify the DNMT1-associated maintenance methylation protein UHRF1 as a mediator of HBG repression through a CRISPR/Cas9 screen. Loss of UHRF1 in the adult-type erythroid cell line HUDEP2 causes global demethylation and HBG activation that is reversed upon localized promoter re-methylation. Conversely, targeted demethylation of the HBG promoters activates their genes in HUDEP2 or primary CD34+ cell-derived erythroblasts. Mutation of MBD2, a CpG-methylation reading component of the NuRD co-repressor complex, recapitulates the effects of promoter demethylation. Our findings demonstrate that localized CpGmethylation at the HBG promoters facilitates gene silencing and identify a potential therapeutic approach for β-hemoglobinopathies via epigenomic editing.
Suggested Citation
Henry W. Bell & Ruopeng Feng & Manan Shah & Yu Yao & James Douglas & Phillip A. Doerfler & Thiyagaraj Mayuranathan & Michael F. O’Dea & Yichao Li & Yong-Dong Wang & Jingjing Zhang & Joel P. Mackay & Y, 2025.
"Removal of promoter CpG methylation by epigenome editing reverses HBG silencing,"
Nature Communications, Nature, vol. 16(1), pages 1-16, December.
Handle:
RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-62177-z
DOI: 10.1038/s41467-025-62177-z
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-62177-z. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.